as of 03-10-2026 3:54pm EST
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | San Francisco |
| Market Cap: | 4.8B | IPO Year: | 2016 |
| Target Price: | $209.69 | AVG Volume (30 days): | 652.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | 61.71 |
| 52 Week Low/High: | $92.52 - $210.01 | Next Earning Date: | 05-25-2026 |
| Revenue: | $747,138,000 | Revenue Growth: | 26.24% |
| Revenue Growth (this year): | 19.58% | Revenue Growth (next year): | 15.95% |
| P/E Ratio: | -89.14 | Index: | N/A |
| Free Cash Flow: | 34.5M | FCF Growth: | N/A |
CHIEF COMM & PRODUCT OFFICER
Avg Cost/Share
$128.44
Shares
4,444
Total Value
$570,804.19
Owned After
61,194
Chief Financial Officer
Avg Cost/Share
$128.45
Shares
3,395
Total Value
$436,076.41
Owned After
37,485
CBO and CLO
Avg Cost/Share
$128.44
Shares
4,357
Total Value
$559,623.89
Owned After
65,532
CHIEF MED/SCI OFCR EVP ADVTECH
Avg Cost/Share
$128.45
Shares
4,027
Total Value
$517,259.17
Owned After
54,906
Chief Accounting Officer
Avg Cost/Share
$128.45
Shares
816
Total Value
$104,814.84
Owned After
17,123
President and CEO
Avg Cost/Share
$128.44
Shares
13,813
Total Value
$1,774,173.93
Owned After
204,155
EVP, Chief Risk Officer
Avg Cost/Share
$128.44
Shares
2,830
Total Value
$363,483.88
Owned After
43,754
EVP Strategic Business Ops
Avg Cost/Share
$128.44
Shares
1,352
Total Value
$173,652.42
Owned After
25,612
CHIEF COMM & PRODUCT OFFICER
Avg Cost/Share
$135.42
Shares
8,967
Total Value
$1,214,301.28
Owned After
61,194
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$135.42
Shares
5,188
Total Value
$702,553.25
Owned After
37,485
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Patterson Chad | IRTC | CHIEF COMM & PRODUCT OFFICER | Mar 2, 2026 | Sell | $128.44 | 4,444 | $570,804.19 | 61,194 | |
| Wilson Daniel G. | IRTC | Chief Financial Officer | Mar 2, 2026 | Sell | $128.45 | 3,395 | $436,076.41 | 37,485 | |
| Murphy Patrick Michael | IRTC | CBO and CLO | Mar 2, 2026 | Sell | $128.44 | 4,357 | $559,623.89 | 65,532 | |
| Turakhia Minang | IRTC | CHIEF MED/SCI OFCR EVP ADVTECH | Mar 2, 2026 | Sell | $128.45 | 4,027 | $517,259.17 | 54,906 | |
| Rosenbaum Marc W. | IRTC | Chief Accounting Officer | Mar 2, 2026 | Sell | $128.45 | 816 | $104,814.84 | 17,123 | |
| Blackford Quentin S. | IRTC | President and CEO | Mar 2, 2026 | Sell | $128.44 | 13,813 | $1,774,173.93 | 204,155 | |
| Shrishrimal Sumi | IRTC | EVP, Chief Risk Officer | Mar 2, 2026 | Sell | $128.44 | 2,830 | $363,483.88 | 43,754 | |
| Smith Mervin | IRTC | EVP Strategic Business Ops | Mar 2, 2026 | Sell | $128.44 | 1,352 | $173,652.42 | 25,612 | |
| Patterson Chad | IRTC | CHIEF COMM & PRODUCT OFFICER | Feb 25, 2026 | Sell | $135.42 | 8,967 | $1,214,301.28 | 61,194 | |
| Wilson Daniel G. | IRTC | Chief Financial Officer | Feb 25, 2026 | Sell | $135.42 | 5,188 | $702,553.25 | 37,485 |
SEC 8-K filings with transcript text
Feb 19, 2026 · 100% conf.
1D
+0.34%
$159.42
5D
-9.42%
$143.91
20D
-4.85%
$151.17
irtc-202602190001388658FALSE00013886582026-02-192026-02-19
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2026 iRhythm Holdings, Inc. (Exact name of Registrant as specified in its charter)
Delaware001-3791841-3421287
(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
699 8th Street, Suite 600 San Francisco, California 94103 (Address of principal executive office) (Zip Code) (415) 632-5700 (Registrant’s telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, Par Value $0.001 Per ShareIRTCThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 19, 2026, iRhythm Holdings, Inc. issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
Exhibit No. Description 99.1 Press release issued by iRhythm Holdings, Inc., dated as of February 19, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 19, 2026 By:/s/ Daniel G. Wilson Daniel Wilson Chief Financial Officer
Oct 30, 2025
irtc-202510300001388658FALSE00013886582025-10-302025-10-30
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter)
Delaware001-3791820-8149544 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
699 8th Street, Suite 600 San Francisco, California 94103 (Address of principal executive office) (Zip Code) (415) 632-5700 (Registrant’s telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, Par Value $0.001 Per ShareIRTCThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Agreement
The information set forth under Item 5.02 regarding the amendment and restatement of the Executive Change in Control and Severance Policy is incorporated by reference into this Item 1.01.
Item 2.02. Results of Operations and Financial Condition.
On October 30, 2025, iRhythm Technologies, Inc. issued a press release regarding its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Amended and Restated Executive Change in Control and Severance Policy
On October 29, 2025, the Board of Directors, upon the recommendation of the Compensation and Human Capital Resources Committee of the Board of Directors, of iRhythm Technologies, Inc. (the “Company”) approved the amendment and restatement of the Company’s existing Executive Change in Control and Severance Policy (the “Existing Policy” and, as restated, the “Restated Policy”). The Restated Policy was approved to make certain enhancements in the event of certain qualifying terminations of employment, both outside of and in connection with a change in control of the Company, to better align with market practices and to preserve the intended retentive and incentive purposes of the policy. The Restated Policy is summarized below.
The Restated Policy provides for certain severance payments and benefits to be provided to a participant in the event such participant’s employment is terminated under specified circumstances as set forth in the Restated Policy, subject to the participant satisfying certain conditions, including the delivery of a release of all claims in favor of the Company. Participants under the Restated Policy include all Vice Presidents and above, including the Company’s named executive officers currently employed by the Company: Quentin Blackford, the Chief Executive Officer, Daniel Wilson, the Chief Financial Officer, Patrick Murphy, the Chief Business Officer and Chief Legal Officer, Chad Patterson, the Chief Commercial & Product Officer, and Minang (Mintu) Turakhia, M.D., M.S., the Chief Medical and Scientific Officer,
Jul 31, 2025
irtc-202507310001388658FALSE00013886582025-07-312025-07-31
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2025 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its charter)
Delaware001-3791820-8149544 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
699 8th Street, Suite 600 San Francisco, California 94103 (Address of principal executive office) (Zip Code) (415) 632-5700 (Registrant’s telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, Par Value $0.001 Per ShareIRTCThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 31, 2025, iRhythm Technologies, Inc. issued a press release regarding its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
Exhibit No. Description 99.1 Press release issued by iRhythm Technologies, Inc., dated as of July 31, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 31, 2025 By:/s/ Daniel Wilson Daniel Wilson Chief Financial Officer
See how IRTC stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IRTC iRhythm Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.